pre randomisation tumour specimen (Foundation Medicine Inc)
Foundation Medicine Inc is a verified supplier 
Foundation Medicine Inc manufactures this product 
99
Structured Review
Foundation Medicine Inc
pre randomisation tumour specimen
Pre Randomisation Tumour Specimen, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 2275 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pre+randomisation+tumour+specimen/FoundationOne+CDx/pm41422862-70-13-20
Average 99 stars, based on 2275 article reviews
Pre Randomisation Tumour Specimen, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 2275 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pre+randomisation+tumour+specimen/FoundationOne+CDx/pm41422862-70-13-20
Average 99 stars, based on 2275 article reviews
pre randomisation tumour specimen - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Next-Generation Sequencing:Article Title: Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial. Article Snippet: Please cite this article as: Schmid PS, McArthur HL, Cortés J, Xu B, Cardoso F, Casalnuovo M, Demirci U, Freitas-Junior R, Ghosh J, Hegg R, Iwata H, Karnaukhov I, Chuken YL, Nechaeva M, Robson ME, Villalobos-Valencia R, Yamashita T, Zurawski B, de Bruin EC, Grinsted L, D’Cruz C, Foxley A, Park YH, Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial, Annals of Oncology (2026), doi: https:// doi.org/10.1016/j.annonc.2025.12.012. |